Close Menu

Precision Oncology News

At ASCO, Blueprint presented positive data on its RET inhibitor pralsetinib across a range of cancers and in a call with investors discussed regulatory plans in lung and thyroid cancers.  

The gap in care suggests that more education and decision support tools are needed to help physicians prescribe drugs based on highly actionable tumor alterations, researchers said.

In a retrospective study, investigators saw a survival benefit among head and neck cancer patients with high TMB treated with checkpoint inhibitors.